103 related articles for article (PubMed ID: 9422083)
1. Inhibitory effect of amiloride on the urokinase plasminogen activators in prostatic cancer.
Ray P; Bhatti R; Gadarowski J; Bell N; Nasruddin S
Tumour Biol; 1998; 19(1):60-4. PubMed ID: 9422083
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice.
Jankun J; Keck RW; Skrzypczak-Jankun E; Swiercz R
Cancer Res; 1997 Feb; 57(4):559-63. PubMed ID: 9044824
[TBL] [Abstract][Full Text] [Related]
3. The urokinase inhibitor p-aminobenzamidine inhibits growth of a human prostate tumor in SCID mice.
Billström A; Hartley-Asp B; Lecander I; Batra S; Astedt B
Int J Cancer; 1995 May; 61(4):542-7. PubMed ID: 7759160
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and preliminary evaluation of amiloride analogs as inhibitors of the urokinase-type plasminogen activator (uPA).
Matthews H; Ranson M; Tyndall JD; Kelso MJ
Bioorg Med Chem Lett; 2011 Nov; 21(22):6760-6. PubMed ID: 21978672
[TBL] [Abstract][Full Text] [Related]
5. Amiloride selectively inhibits the urokinase-type plasminogen activator.
Vassalli JD; Belin D
FEBS Lett; 1987 Apr; 214(1):187-91. PubMed ID: 3106085
[TBL] [Abstract][Full Text] [Related]
6. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
McGowen R; Biliran H; Sager R; Sheng S
Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
[TBL] [Abstract][Full Text] [Related]
7. Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA).
Rabbani SA; Harakidas P; Davidson DJ; Henkin J; Mazar AP
Int J Cancer; 1995 Dec; 63(6):840-5. PubMed ID: 8847143
[TBL] [Abstract][Full Text] [Related]
8. Time and dose dependency of the suppression of pulmonary metastases of rat mammary cancer by amiloride.
Evans DM; Sloan-Stakleff K; Arvan M; Guyton DP
Clin Exp Metastasis; 1998 May; 16(4):353-7. PubMed ID: 9626814
[TBL] [Abstract][Full Text] [Related]
9. An inhibitor of urokinase and tissue plasminogen activators in Dunning R3327H prostate tumors of rats treated with D-Trp6-LH-RH.
Hierowski MT; Schally AV
Horm Res; 1985; 21(2):124-35. PubMed ID: 3156799
[TBL] [Abstract][Full Text] [Related]
10. 6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.
Buckley BJ; Aboelela A; Minaei E; Jiang LX; Xu Z; Ali U; Fildes K; Cheung CY; Cook SM; Johnson DC; Bachovchin DA; Cook GM; Apte M; Huang M; Ranson M; Kelso MJ
J Med Chem; 2018 Sep; 61(18):8299-8320. PubMed ID: 30130401
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen activator activity of normal and retinoic acid-treated post-implantation embryos.
Knoops B; Lison D; Collette C; Lauwerys R; Picard JJ
Biochem Pharmacol; 1990 May; 39(10):1545-8. PubMed ID: 2110809
[TBL] [Abstract][Full Text] [Related]
12. 6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease.
Buckley BJ; Majed H; Aboelela A; Minaei E; Jiang L; Fildes K; Cheung CY; Johnson D; Bachovchin D; Cook GM; Huang M; Ranson M; Kelso MJ
Bioorg Med Chem Lett; 2019 Dec; 29(24):126753. PubMed ID: 31679971
[TBL] [Abstract][Full Text] [Related]
13. Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride.
Jankun J; Skrzypczak-Jankun E
Cancer Biochem Biophys; 1999 Jul; 17(1-2):109-23. PubMed ID: 10738907
[TBL] [Abstract][Full Text] [Related]
14. Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model.
Alonso DF; Farías EF; Ladeda V; Davel L; Puricelli L; Bal de Kier Joffé E
Breast Cancer Res Treat; 1996; 40(3):209-23. PubMed ID: 8883963
[TBL] [Abstract][Full Text] [Related]
15. Effects of castration on plasminogen activator activities and plasminogen activator inhibitor type 1 in the rat ventral prostate.
Wilson MJ; Ludowese C; Sinha AA; Estensen RD
Prostate; 1996 Apr; 28(4):239-50. PubMed ID: 8602400
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of plasminogen activation protects against ganglion cell loss in a mouse model of retinal damage.
Zhang X; Chaudhry A; Chintala SK
Mol Vis; 2003 Jun; 9():238-48. PubMed ID: 12813409
[TBL] [Abstract][Full Text] [Related]
17. Plasminogen activator activities in short-term tissue cultures of benign prostatic hyperplasia and prostatic carcinoma.
Festuccia C; Vincentini C; di Pasquale AB; Aceto G; Zazzeroni F; Miano L; Bologna M
Oncol Res; 1995; 7(3-4):131-8. PubMed ID: 8555646
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen activator and metalloprotease activities of Du-145, PC-3, and 1-LN-PC-3-1A human prostate tumors grown in nude mice: correlation with tumor invasive behavior.
Wilson MJ; Sinha AA
Cell Mol Biol Res; 1993; 39(8):751-60. PubMed ID: 7951414
[TBL] [Abstract][Full Text] [Related]
19. PD98059-inhibited invasion of Dunning rat prostate cancer cells involves suppression of motility but not MMP-2 or uPA secretion.
Suthiphongchai T; Phimsen S; Sakulkhu U; Tohtong R
Oncol Rep; 2006 Jun; 15(6):1605-10. PubMed ID: 16685402
[TBL] [Abstract][Full Text] [Related]
20. Regulation of urokinase production by androgens in human prostate cancer cells: effect on tumor growth and metastases in vivo.
Xing RH; Rabbani SA
Endocrinology; 1999 Sep; 140(9):4056-64. PubMed ID: 10465276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
